Why Peptide Researchers Should Care About the FDA's Compounding Rules

If you buy peptides for research, a change brewing at the FDA could affect what you can actually get and whether you can trust it.

What's Happening at the FDA

The FDA is considering loosening restrictions on something called "compounding." Compounding is when a pharmacy makes a customized version of a drug, in this case, peptides, tailored for a specific need. Right now, compound pharmacies operate in a gray zone. They can make peptides, but they're supposed to follow strict rules about quality and labeling.

Hims & Hers, a telehealth company that sells wellness and weight-loss products, stands to benefit if the FDA makes compounding easier. They currently partner with compounding pharmacies to offer peptides like semaglutide and tirzepatide at lower prices than brand-name versions. If restrictions ease, more companies could enter this space.

For you as a researcher, this matters because it could change where and how you source your peptides.

What This Means For Your Lab Work

Here's the reality: not all peptides are created equal. When you order from a reputable supplier, you're getting a compound with known purity, tested and verified. When you buy from a compounding pharmacy, you're relying on their quality controls, and those vary widely.

Some compound pharmacies do excellent work. Others cut corners. A 2022 FDA inspection found that nearly half of compounding pharmacies had quality problems. The most common issues were contamination, wrong potency, and unclear labeling.

When you reconstitute a peptide, you're trusting that what went into that vial matches what's on the label. If the purity is lower than stated, your dosing math gets thrown off. If there are contaminants, your experiment results become unreliable. You're not just wasting money, you're potentially invalidating weeks of work.

What Researchers Need to Watch

If the FDA loosens these rules, expect more players to enter the peptide market. More options sound good, but they come with a caveat: you'll need to be more careful about who you trust.

Before you buy from a new supplier, ask for a certificate of analysis (COA). This document tells you exactly what's in the vial, the purity percentage, any contaminants found, and the batch number. Any reputable supplier should provide this without hesitation.

Also pay attention to how the peptide was stored and shipped. Peptides degrade when exposed to heat or light. If you're ordering a fragile compound like a growth hormone releasing peptide, it should arrive on dry ice or with cold packs. If a package shows up at room temperature, that's a red flag.

• Check the COA: Always verify purity and batch information before opening the vial.
• Inspect shipping: Cold-chain peptides should arrive cold. Warm packages mean degraded product.
• Know your supplier: Established research suppliers have track records you can verify.
• Store properly: Once in your hands, keep peptides at the correct temperature, most need refrigeration.

The Bottom Line

Regulatory changes in the peptide space aren't just business news. They're practical concerns for anyone running experiments. More competition could drive prices down, but it could also introduce more variability into your supply chain.

The researchers who get consistent, reliable results are the ones who pay attention to sourcing. Know your supplier, verify your materials, and treat every vial with the scrutiny it deserves.

Frequently asked questions

Why should researchers care about FDA compounding rules?

Changes affect peptide availability and quality; more suppliers means more variation in purity and reliability.

How can I verify peptide quality before buying?

Always request a certificate of analysis (COA) showing purity, contaminants, and batch information.

What are red flags when ordering peptides?

Warm shipping, missing COA, vague supplier information, and prices significantly below market rates.

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about FDA compounding rules and peptide sourcing

• "Compounded" does not mean "FDA quality-checked." A compounded preparation is not reviewed by the FDA for identity, purity, or strength before it reaches your bench. Treating a compounded vial like an approved reference standard is a common mistake.
• A low price is read as a bargain, not a warning. A price far below the market can mean a batch that was never tested the way an established research supplier tests its material. Cheap material that fails your assay is not a saving.
• A certificate of analysis is trusted on sight. A COA only tells you something if the batch number on the paper matches the number on the vial in your hand, and if an independent lab ran it. A COA with no matching batch is just a piece of paper.
• "More suppliers" is assumed to be automatically good. If the rules loosen, more sellers enter the market, but that also means more variation between lots. A result you got from one batch may not repeat with the next one.
• Regulatory news is filed as business news. A change to compounding rules can change what actually ends up in a vial. At the bench that is a reproducibility problem, not just a market story, so it belongs in your notes.

From our bench: If you have run the same peptide from two different suppliers, or from two different lots of one supplier, we want your raw notes. Record each batch number, whether the COA number actually matched the vial, and any difference you observed in the reconstituted material (cloudiness, particulates, or how the recovered mass came back on your scale). Send us the numbers you measured, not a summary, and we will add verified bench observations to this page.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother. 2026. PMID 41689811
5. Liu G, Jarema M, Mo M, Stievater T. Navigating compounded semaglutide: what health care providers need to know. Am J Manag Care. 2025. PMID 40966636
6. Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. J Am Pharm Assoc. 2023. PMID 37392810